Skip to main content
SpringerLink
Log in

Data exclusivity for biologics

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

An Erratum to this article was published on 01 June 2011

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Cumulative net present value (NPV) of cash flows for a representative biologic with various scenarios for market exclusivity.
Figure 2: Influence of data exclusivity and patent protection on break-even points for a representative biologic portfolio.

References

  1. Title VII of the Patient Protection and Affordable Care Act of 2010, Pub. L. No. 111–48, Improving Access to Innovative Medical Therapies—Subtitle (2010).

  2. Grabowski, H. Follow-on biologics: data exclusivity and the balance between innovation and competition. Nature Rev. Drug Discov. 7, 479–488 (2008).

    Article  CAS  Google Scholar 

  3. Federal Trade Commission (FTC). Emerging Health Care Issues: Follow-on Biologic Drug Competition. Federal Trade Commission Report | June 2009. FTC website [online], (2009).

Download references

Author information

Authors and Affiliations

  1. Henry Grabowski is at Duke University, Durham, North Carolina 27708, USA.,

    Henry Grabowski

  2. Genia Long and Richard Mortimer are at Analysis Group Inc., Boston, Massachusetts 02199, USA.,

    Genia Long & Richard Mortimer

Authors
  1. Henry Grabowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Genia Long
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard Mortimer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Henry Grabowski.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information Box S1

Details of modelling and analysis (PDF 356 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grabowski, H., Long, G. & Mortimer, R. Data exclusivity for biologics. Nat Rev Drug Discov 10, 15–16 (2011). https://doi.org/10.1038/nrd3277

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3277

  • Springer Nature Limited

This article is cited by

Search

Navigation